ArticleBiotechnic & histochemistry : official publication of the Biological Stain Commission2013
MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells.
Article in Biotechnic & histochemistry : official publication of the Biological Stain Commission, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Review
- miR‑100: A key tumor suppressor regulatory factor in human malignant tumors (Review).International journal of molecular medicine · 2025Review
- MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential.Frontiers in cell and developmental biology · 2024Review
- WISP1 induces ovarian cancer via the IGF1/αvβ3/Wnt axis.Journal of ovarian research · 2022Article
- Differential expression of microRNA between triple negative breast cancer patients of African American and European American descent.Biotechnic & histochemistry : official publication of the Biological Stain Commission · 2022Article
- Dysregulation of miRNAs Targeting the IGF-1R Pathway in Pancreatic Ductal Adenocarcinoma.Cells · 2021Article
- miR-100 Inhibits Cell Growth and Proliferation by Targeting HOXA1 in Nasopharyngeal Carcinoma.OncoTargets and therapy · 2020Article
- Review
- Association of miR-100 expression with clinicopathological features and prognosis of patients with lung cancer.Oncology letters · 2019Article
- Circulating microRNA-99 family as liquid biopsy marker in pancreatic adenocarcinoma.Journal of cancer research and clinical oncology · 2018Article
- Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy.International journal of molecular sciences · 2016Review
- Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review).International journal of oncology · 2015Review
- Potential role of miR-100 in cancer diagnosis, prognosis, and therapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Role of miR-100 in the radioresistance of colorectal cancer cells.American journal of cancer research · 2015Article
- MicroRNAs in pancreatic malignancy: progress and promises.Cancer letters · 2014Review
- MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans.Biotechnic & histochemistry : official publication of the Biological Stain Commission · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with pancreatic adenocarcinoma have the lowest 5 year survival rate and yearly rates of incidence are nearly equal to the mortality rates. Long term cure rates by standard therapies are disappointing owing to disseminated disease at diagnosis and chemotherapeutic resistance. New therapeutic targets are necessary to decrease the progression of pancreatic cancer and the ability to identify targets specific to metastasis would improve patient care. We evaluated the levels of microRNA of metastatic and non-metastatic cell lines. The expression levels of microRNAs and mRNAs were determined using microarray analysis to examine and compare five pancreatic cancer cell lines, two that can metastasize in vivo (S2VP10 and S2CP9) and three that do not metastasize (MiaPaCa2, Panc-1 and ASPC-1). MicroRNA analysis indicated an increase in miR-100 and a decrease in miR-138 expression in metastatic cancer cells. Microarray analysis of different expressions of mRNAs in metastatic and non-metastatic pancreatic cell lines also indicated significantly increased insulin growth factor-1 receptor (IGF1-R) expression in metastatic pancreatic cancer cell lines compared to non-metastatic pancreatic cancer cell lines. To confirm microarray analysis results, western blot and immunocytochemistry were performed. Western blot revealed that IGF1-R expression exhibited in metastatic cancer cell lines a seven-fold increase compared to non-metastatic cell lines. In addition, downstream expressions of the proteins, GRB2 and phosphorylated PI3K, also were increased in aggressive cancer cell lines. Immunocytochemistry confirmed the linkage of IGF1-R to miR-100, because cells transfected with miR-100 inhibitor showed a decrease in IGF1-R. Cells transfected with a miR-138 mimic, however, did not affect IGF1-R expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.